Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Voyager Therapeutics (VYGR) Non Operating Income (2016 - 2025)

Voyager Therapeutics' Non Operating Income history spans 10 years, with the latest figure at -$8.1 million for Q4 2025.

  • For Q4 2025, Non Operating Income rose 41.84% year-over-year to -$8.1 million; the TTM value through Dec 2025 reached $1.6 million, up 165.11%, while the annual FY2025 figure was $1.6 million, 165.11% up from the prior year.
  • Non Operating Income for Q4 2025 was -$8.1 million at Voyager Therapeutics, down from $8.9 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $11.7 million in Q4 2023 and bottomed at -$13.9 million in Q4 2024.
  • The 5-year median for Non Operating Income is $801500.0 (2021), against an average of $1.0 million.
  • The largest annual shift saw Non Operating Income tumbled 3236.96% in 2021 before it skyrocketed 5912.9% in 2023.
  • A 5-year view of Non Operating Income shows it stood at $650000.0 in 2021, then surged by 46.62% to $953000.0 in 2022, then surged by 1129.91% to $11.7 million in 2023, then crashed by 218.86% to -$13.9 million in 2024, then soared by 41.84% to -$8.1 million in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Non Operating Income are -$8.1 million (Q4 2025), $8.9 million (Q3 2025), and $427000.0 (Q2 2025).